1.Merler, S, Ajelli, M. The role of population heterogeneity and human mobility in the spread of pandemic influenza. Proceedings of the Royal Society B: Biological Sciences 2010; 277: 557–565.
2.Merler, S, Ajelli, M, Rizzo, C. Age-prioritized use of antivirals during an influenza pandemic. BMC Infectious Diseases 2009; 9: 117.
3.Ciofi degli Atti, ML, et al. Mitigation measures for pandemic influenza in Italy: an individual based model considering different scenarios. PLoS ONE 2008; 3: e1790.
4.Ferguson, NM, et al. Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 2005; 437: 209–214.
5.Halloran, ME, et al. Modeling targeted layered containment of an influenza pandemic in the United States. Proceedings of the National Academy of Sciences USA 2008; 105: 4639–4645.
6.Wu, JT, et al. Reducing the impact of the next influenza pandemic using household-based public health interventions. PLoS Medicine 2006; 3: e361.
7.Germann, TC, et al. Mitigation strategies for pandemic influenza in the United States. Proceedings of the National Academy of Sciences USA 2006; 103: 5935–5940.
8.Davey, WJ, et al. Effective, robust design of community mitigation for pandemic influenza: a sytematic examination of proposed US guidance. PLoS ONE 2008; 3: e2606.
9.Longini, IM Jr., et al. Containing pandemic influenza at the source. Science 2005; 309: 1083–1087.
10.Ferguson, NM, et al. Strategies for mitigating an influenza pandemic. Nature 2006; 442: 448–452.
12.Rizzo, C, et al. Enhanced epidemiological surveillance of influenza A(H1N1)v in Italy. Eurosurveillance 2009; 14: pii=19266.
14.Balcan, D, et al. Seasonal transmission potential and activity peaks of the new influenza A(H1N1): a Monte Carlo likelihood analysis based on human mobility. BMC Medicine 2009; 7: 45.
15.Hayden, FG, et al. Use of the Oral Neuraminidase Inhibitor Oseltamivir in Experimental Human Influenza. Journal of the American Medical Association 1999; 282: 1240–1246.
18.Fraser, C, et al. Pandemic potential of a strain of influenza A (H1N1): early findings. Science 2009; 324: 1557–1561.
19.Cauchemez, S, et al. Estimating the impact of school closure on influenza transmission from sentinel data. Nature 2008; 452: 750–754.
21.Reichert, T, et al. Does glycosylation as a modifier of original antigenic Sin explain the case age distribution and unusual toxicity in pandemic novel H1N1 influenza? BMC Infectious Diseases 2010; 10: 5.
22.Chowell, G, et al. Severe respiratory disease concurrent with the circulation of H1N1 influenza. New England Journal of Medicine 2009; 361: 674–679.
23.Yang, Y, et al. The transmissibility and control of pandemic influenza A (H1N1) virus. Science 2009; 326: 729–733.
24.Munayco, C, et al. Epidemiological and transmissibility analysis of influenza A(H1N1)v in a southern hemisphere setting: Peru. Eurosurveillance 2009; 14: 19299.
25.Nishiura, H, et al. Transmission potential of the new influenza A(H1N1) virus and its age-specificity in Japan. Eurosurveillance 2009; 14: 19227.
26.Boelle, PY, Bernillon, P, Desenclos, J. A preliminary estimation of the reproduction ratio for new influenza A(H1N1) from the outbreak in Mexico, March–April 2009. Eurosurveillance 2009; 14: 19205.
27.Singer, AC, et al. Meeting report: risk assessment of Tamiflu use under pandemic conditions. Environmental Health Perspectives 2008; 116: 1563–1567.
28.Cauchemez, S, et al. Household transmission of 2009 pandemic influenza A (H1N1) virus in the United States. New England Journal of Medicine 2009; 361: 2619–2627.
29.Ghani, AC, et al. The early transmission dynamics of H1N1pdm influenza in the United Kingdom. PLoS Currents: Influenza 2009; RRN1130.
30.Lunelli, A, et al. Understanding the dynamics of seasonal influenza in Italy: an analysis of disease incidence and population susceptibility. Presented at the European Scientific Conference on Applied Infectious Disease Epidemiology, Stockholm, Sweden, 26–28 October 2009.
31.Centers for Disease Control and Prevention. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. Morbidity and Mortality Weekly Report 2009; 58: 521–524.
32.Zimmer, S, Burke, D. Historical perspective-emergence of influenza A (H1N1) viruses. New England Journal of Medicine 2009; 361: 279–285.
33.Shaman, J, Kohn, M. Absolute humidity modulates influenza survival, transmission, and seasonality. Proceedings of the National Academy of Sciences USA 2009; 106: 3243–3248.
34.Shaman, J, et al. Absolute humidity and the seasonal onset of influenza in the continental United States. PLoS Biology 2010; 8: e1000316.
35.Miller, MA, et al. The signature features of influenza pandemics – implications for policy. New England Journal of Medicine 2009; 360: 2595–2598.
36.Rizzo, C, et al. Trends for influenza-related deaths during pandemic and epidemic seasons, Italy, 1969–2001. Emerging Infectious Diseases 2007; 13: 694–699.